Clinical Trial Detail

NCT ID NCT02342353
Title Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + Pacritinib

Age Groups: adult

No variant requirements are available.